Back to All Trials
RecruitingPhase 2Neurology

Cognitive Enhancement Study for Mild Alzheimer's Disease

$100
per visit
18 months
Duration
12
Total Visits
144
Spots Remaining

About This Study

This trial evaluates a novel oral medication designed to slow cognitive decline in patients with mild Alzheimer's disease. The treatment targets amyloid plaques and tau proteins associated with the disease.

Study Objectives

To assess changes in cognitive function using standardized assessments over 18 months.

Eligibility Requirements

Inclusion Criteria

  • Adults 55-85 years old
  • Diagnosis of mild Alzheimer's disease
  • MMSE score between 20-26
  • Reliable study partner available
  • Stable medications for 3 months

Exclusion Criteria

  • Other forms of dementia
  • Major psychiatric disorder
  • Significant cardiovascular disease
  • MRI contraindications

Frequently Asked Questions

Study Location

UC San Diego Health
San Diego, CA 92093
Map View

Research Team

Dr. Emily Watson
UC San Diego School of Medicine
Memory Disorders Clinic
alzheimers.study@ucsd.edu(858) 555-0789

Study Timeline

Start DateFebruary 1, 2024
End DateAugust 1, 2025
Enrollment156 / 300